Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$51.76 -1.8%	$49.94	$21.34 ▼ $58.40	$4.20B	-0.15	1.05 million shs	980,244 shs
KRYS Krystal Biotech	$147.73 -1.8%	$135.75	$122.80 ▼ $219.34	$4.35B	0.67	287,552 shs	322,915 shs
PRAX Praxis Precision Medicines	$51.89 -3.2%	$42.42	$26.70 ▼ $91.83	$1.09B	2.6	367,636 shs	396,506 shs
RNA Avidity Biosciences	$31.70 -5.6%	$30.61	$21.51 ▼ $56.00	$4.05B	0.91	1.40 million shs	2.12 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	-1.84%	+2.76%	-6.94%	+38.25%	+88.56%
KRYS Krystal Biotech	-1.78%	+3.06%	+7.78%	-10.30%	-28.93%
PRAX Praxis Precision Medicines	-3.19%	+10.97%	+17.13%	+73.95%	+1.79%
RNA Avidity Biosciences	-5.57%	+8.38%	+1.05%	+23.06%	-30.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.5192 of 5 stars	3.5	1.0	4.7	2.1	0.8	0.0
KRYS Krystal Biotech	4.6272 of 5 stars	3.5	1.0	4.7	2.9	3.3	1.9
PRAX Praxis Precision Medicines	2.2504 of 5 stars	4.4	1.0	0.0	1.6	1.7	0.0
RNA Avidity Biosciences	2.3294 of 5 stars	4.5	0.0	0.0	3.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	59.39% Upside
KRYS Krystal Biotech	3.00	Buy	$213.75	44.69% Upside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$94.11	81.37% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	109.32% Upside

Current Analyst Ratings Breakdown

Latest PRAX, KRYS, AKRO, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
7/9/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$155.00 ➝ $176.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/24/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
KRYS Krystal Biotech	$333.45M	12.80	$4.56 per share	32.43	$32.90 per share	4.49
PRAX Praxis Precision Medicines	$8.55M	123.63	N/A	N/A	$23.90 per share	2.17
RNA Avidity Biosciences	$10.90M	350.50	N/A	N/A	$11.94 per share	2.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	35.51	14.66	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest PRAX, KRYS, AKRO, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.20	N/A	N/A	N/A	$95.42 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
KRYS Krystal Biotech	N/A	9.65	9.27
PRAX Praxis Precision Medicines	N/A	8.44	8.44
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
KRYS Krystal Biotech	86.29%
PRAX Praxis Precision Medicines	67.84%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
KRYS Krystal Biotech	13.70%
PRAX Praxis Precision Medicines	2.70%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

PRAX, KRYS, AKRO, and RNA Headlines

Recent News About These Companies

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive

July 14 at 4:24 PM | seekingalpha.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's Why

July 14 at 11:11 AM | marketbeat.com

Avidity Biosciences price target raised to $70 from $60 at Evercore ISI

July 12, 2025 | msn.com

Alps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 12, 2025 | marketbeat.com

The Goldman Sachs Group Upgrades Avidity Biosciences (NASDAQ:RNA) to Buy

July 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 6, 2025 | marketbeat.com

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...

June 27, 2025 | benzinga.com

Avidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal year

June 26, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts

June 26, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

June 24, 2025 | investing.com

SG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 23, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, KRYS, AKRO, and RNA Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$51.76 -0.97 (-1.84%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$51.63 -0.13 (-0.25%)

As of 07/15/2025 05:11 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$147.73 -2.68 (-1.78%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$147.79 +0.06 (+0.04%)

As of 07/15/2025 06:24 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Praxis Precision Medicines NASDAQ:PRAX

$51.89 -1.71 (-3.19%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$51.81 -0.08 (-0.15%)

As of 04:01 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$31.70 -1.87 (-5.57%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$32.00 +0.30 (+0.95%)

As of 07/15/2025 07:55 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time